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Abstract: The chemokine-like receptor 1 (CMKLR1) ligands resolvin E1 and chemerin are known to
modulate inflammatory response. The progression of non-alcoholic fatty liver disease (NAFLD) to
non-alcoholic steatohepatitis (NASH) is associated with inflammation. Here it was analyzed whether
hepatic CMKLR1 expression is related to histological features of NASH. Therefore, CMKLR1 mRNA
was quantified in liver tissue of 33 patients without NAFLD, 47 patients with borderline NASH
and 38 patients with NASH. Hepatic CMKLR1 mRNA was not associated with gender and body mass
index (BMI) in the controls and the whole study group. CMKLR1 expression was similar in controls
and in patients with borderline NASH and NASH. In male patients weak positive correlations with
inflammation, fibrosis and NASH score were identified. In females CMKLR1 was not associated with
features of NAFLD. Liver CMKLR1 mRNA tended to be higher in type 2 diabetes patients of both
genders and in hypercholesterolemic women. In summary, this study shows that hepatic CMKLR1
mRNA is weakly associated with features of NASH in male patients only.
Keywords: liver steatosis; fibrosis; gender; type 2 diabetes
1. Introduction
Non-alcoholic fatty liver disease (NAFLD) is a widespread cause of chronic liver injury and its
progressive form non-alcoholic steatohepatitis (NASH) is characterized by hepatic inflammation and
fibrosis [1,2]. NAFLD is related to the metabolic syndrome, and importantly, these patients have
a high prevalence of developing hypertension, type 2 diabetes and dyslipidemia [3]. Chemokine-like
receptor 1 (CMKLR1) is expressed by immune cells including subsets of dendritic cells, macrophages
and natural killer cells [4,5]. The adipokine chemerin attracts CMKLR1-expressing cells to sites of
inflammation [4,5]. Hepatic chemerin levels are changed in NAFLD, suggesting a function of this
chemoattractant factor herein [6–8]. Importantly, higher chemerin expression has been described in
human NASH while levels are unchanged in patients with borderline NASH and even reduced in
human fatty liver [6–8]. Serum chemerin is increased in obesity and positive associations with serum
lipids, blood glucose and blood pressure suggest a function of this chemokine in metabolic diseases [9].
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Data on serum chemerin in NAFLD are not concordant and higher as well as normal levels have been
described [10].
CMKLR1 also binds the potent anti-inflammatory mediator resolvin E1 which is generated from
ω-3 eicosapentaenoic acid [11].
CMKLR1 deficiency in mice is not related to changes in body weight, inflammation, glucose
tolerance and dyslipidemia. Importantly, comparable results have been obtained in animals fed
a standard chow and mice given a high-fat diet [12]. In a second study, a high-fat, high-cholesterol diet
did not differentially affect body weight and insulin resistance in CMKLR1-null mice and the respective
control animals. Of note, hepatic inflammation and expression of fibrotic genes is unchanged in the
liver of CMKLR1-deficient mice [13]. Nevertheless, reduced body weight and body fat irrespective of
low- or high-fat diet has also been reported in CMKLR1 knock-out mice. Despite decreased hepatic
and adipose tissue inflammation, these animals have impaired glucose disposal in muscle and fat [14].
CMKLR1 is highly abundant in the liver and is expressed by primary human hepatocytes, hepatic
stellate cells, Kupffer cells and bile duct cells [15]. In patients with chronic hepatitis C, liver CMKLR1
mRNA is, however, not related to the inflammatory activity grade. CMKLR1 mRNA levels are
comparable in males and females and expression is significantly reduced in women with advanced
liver fibrosis [16].
In human NASH liver, CMKLR1 mRNA is even induced and IL-6 is suggested to contribute to
CMKLR1 upregulation [7]. Associations of hepatic CMKLR1 expression with hepatocyte ballooning,
lobular inflammation and fibrosis have not been identified in human NAFLD [7]. The limitation of
this study is that only three patients with NASH were enrolled [7]. To our knowledge, gender-specific
expression of CMKLR1 in human NAFLD has not been analyzed so far.
Here, hepatic CMKLR1 was quantified in a relatively large cohort of patients with histologically
proven NAFLD. Analysis was performed for both genders separately to identify possible
sex-related differences.
2. Results
2.1. Hepatic Chemokine-Like Receptor 1 (CMKLR1) mRNA in the Human Liver
Recently, Döcke et al. analyzed CMKLR1 mRNA in 34 controls, 10 patients with a NASH score
of 3–4 (undefined or borderline NASH) and three patients with a score equal or above 5 [7]. Because
in that cohort the number of patients with definite NASH was quite small, we decided to determine
CMKLR1 mRNA in a larger study group. CMKLR1 mRNA was measured in a cohort of 118 patients
including 33 controls with normal liver, 47 patients with a NASH score ranging from 1.0 to 4.5
(borderline NASH) and 38 patients with a NASH score equal or above 5 (Table 1).
Table 1. Characteristics of the cohort enrolled in the present study. Data are given as median values and
range of the values. Uppercase numbers are shown where data were not available for all of the patients.
Significant differences between controls and patients with borderline non-alcoholic steatohepatitis
(NASH) are identified by *, between controls and patients with NASH with # and between patients
with borderline NASH and NASH with &.
Control Borderline NASH NASH p-Values
Males/Females 16/17 22/25 24/14
Age 58 (20–82) 60 (24–84) 66 (33–82) 0.015 #
Body mass index (BMI) kg/m2 24.7 (18.3–30.5) 28.0 (22.0–46.0) 28.4 (21.0–57.7) <0.001 *,#
Type 2 Diabetes 0 4 11 0.01 #
Hypertension 7 21 17
Hypercholesterolemia 0 4 10
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Table 1. Cont.
Control Borderline NASH NASH p-Values
Alanine aminotransferase U/L 21 (8–50) 32 35 (17–623) 36 32 (10–984) 35 <0.001 *,#
Aspartate aminotransferase U/L 23 (8–42) 27 31 (11–688) 35 30 (9–389) 34
0.014 *
0.012 #
Alkaline phosphatase U/L 102 (46–203) 29 97 (37–444) 36 91 (45–826) 35
Bilirubin mg/dL 0.6 (0.19–1.95) 30 0.56 (0.19–1.99) 37 0.53 (0.20–0.53) 36
Steatosis 0 (0–0) 2 (1–2) 2.5 (1–3) <0.001 *,#,&
Inflammation 0 (0–0) 0 (0–2) 2 (0–3) 0.005 *<0.001 #,&
Fibrosis 0 (0–0) 0 (0–2) 2 (0–4) 0.047 *<0.001 #,&
NASH Score 0 (0–0) 2 (1–4.5) 6 (5–9) <0.001 *,#,&
Indications for surgery (hepatocellular carcinoma, adenoma, hepatic metastases of extrahepatic
tumours, focal nodular hyperplasia of the liver and cholangiocarcinoma) were not associated with
altered CMKLR1 mRNA levels in the liver tissues used herein (Figure 1A).
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Figure 1. CMKLR1 mRNA (normalized for 18S rRNA) in the human liver. (A) CMKLR1 mRNA in 
liver tissues of patients stratified for surgery indications (M, liver metastases of extrahepatic 
tumours; CCC, cholangiocarcinoma; HCC, hepatocellular carcinoma; FNH, focal nodular 
hyperplasia of the liver; Aden., adenoma); (B) CMKLR1 mRNA in the liver of normal weight (Body 
mass index (BMI) ≤ 25 kg/m2), overweight (BMI > 25 and < 30 kg/m2) and corpulent (BMI ≥ 30 kg/m2) 
patients; (C) CMKLR1 mRNA in female (F) and male (M) liver. 
In the patients with normal liver and in the whole study group, CMKLR1 mRNA did not 
correlate with age (r = −0.249, p = 0.162 in the control group and r = 0.050, p = 0.596 in the whole 
cohort) or Body mass index (BMI) (r = −0.189, p = 0.292 in the control group and r = 0.057, p = 0.546 in 
the whole cohort; data not shown). CMKLR1 mRNA was similarly expressed in the liver of 
normal-weight (BMI ≤ 25 kg/m2), overweight (BMI > 25 and < 30 kg/m2) and obese patients (BMI ≥ 30 
kg/m2) (Figure 1B). CMKLR1 mRNA was not related to gender (Figure 1C). 
2.2. Hepatic CMKLR1 mRNA in Human Non-Alcoholic Fatty Liver Disease (NAFLD) 
In patients with definite NASH (NASH score ≥ 5), CMKLR1 mRNA was not significantly 
increased compared to controls and compared to patients with borderline NASH (NASH score < 5) 
(Figure 2A). When the first two groups with similar median values of CMKLR1 mRNA were 
combined, levels were significantly lower compared to NASH patients (Figure 2B). Receiver 
operating characteristic (ROC) curve analysis (Figure 2C) revealed an area under the curve (AUC) of 
0.648 excluding analysis of CMKLR1 mRNA as a tool for NASH diagnosis. Alanine aminotransferase 
(r = 0.025, p = 0.802), aspartate aminotransferase (r = −0.79, p = 0.447), alkaline phosphatase (r = 0.139, 
p = 0.167) and bilirubin (r = −0.104, p = 0.295) in serum were not associated with hepatic CMKLR1 
mRNA (data not shown). CMKLR1 did not correlate with steatosis grade (r = 0.146, p = 0.114) but 
positively correlated with inflammation (r = 0.248, p = 0.007), fibrosis (r = 0.425, p < 0.001) and NASH 
score (r = 0.272, p = 0.003) (Figure 2D-F and data not shown). 
Type 2 diabetes, hypertension and dyslipidemia are commonly diagnosed in NASH patients 
[3]. Systemic chemerin positively correlates with low-density lipoprotein cholesterol, insulin 
resistance and systolic as well as diastolic blood pressure [9]. Whether hepatic CMKLR1 is 
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in liver tissues of patient s fied for surgery indications (M, liver metastases of extr hepatic
tumo rs; CCC, cholangi carcinoma; HCC, hepatocellular carcinoma; FNH, focal nodular hyperplasia
of the liver; Aden., adenoma); (B) CMKLR1 mRNA in the liver of normal weight (Body mass index
(BMI) ≤ 25 kg/m2), overweight (BMI > 25 and < 30 kg/m2) and corpulent (BMI ≥ 30 kg/m2) patients;
(C) CMKLR1 mRNA in female (F) and male (M) liver.
In the patients with normal liver and in the whole study group, CMKLR1 mRNA did not correlate
with age (r = −0.249, p = 0.162 in the control group and r = 0.050, p = 0.596 in the whole cohort) or
Body mass index (BMI) (r = −0.189, p = 0.292 in the control group and r = 0.057, p = 0.546 in the
whole cohort; data not shown). CMKLR1 mRNA was similarly expressed in the liver of normal-weight
(BMI ≤ 25 kg/m2), overweight (BMI > 25 and < 30 kg/m2) and obese patients (BMI ≥ 30 kg/m2)
(Figure 1B). CMKLR1 mRNA was not related to gender (Figure 1C).
2.2. Hepatic CMKLR1 mRNA i Human Non-Alcoholic Fatty Liver Disease ( FLD)
In patients with definite NASH (NASH score≥ 5), CMKLR1 mRNA was not significantly increased
compared to controls and compared to patients with borderline NASH (NASH score < 5) (Figure 2A).
When the first two groups with similar median values of CMKLR1 mRNA were combined, levels
were signifi antly lower compared to NASH p tients (Figure 2B). Receiver operating charact ristic
(ROC) curve analysis (Figure 2C) revealed an area under the curve (AUC) of 0.648 excluding analysis
of CMKLR1 mRNA as a tool for NASH diagnosis. Alanin aminotransferase (r = 0.025, p = 0.802),
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aspartate aminotransferase (r = −0.79, p = 0.447), alkaline phosphatase (r = 0.139, p = 0.167) and
bilirubin (r = −0.104, p = 0.295) in serum were not associated with hepatic CMKLR1 mRNA (data not
shown). CMKLR1 did not correlate with steatosis grade (r = 0.146, p = 0.114) but positively correlated
with inflammation (r = 0.248, p = 0.007), fibrosis (r = 0.425, p < 0.001) and NASH score (r = 0.272,
p = 0.003) (Figure 2D–F and data not shown).
Type 2 diabetes, hypertension and dyslipidemia are commonly diagnosed in NASH patients [3].
Systemic chemerin positively correlates with low-density lipoprotein cholesterol, insulin resistance and
systolic as well as diastolic blood pressure [9]. Whether hepatic CMKLR1 is associated with metabolic
diseases such as hypercholesterolemia or type 2 diabetes has not been evaluated to our knowledge
so far.
CMKLR1 mRNA was similar in the 14 patients with and those without hypercholesterolemia
(data not shown). In the 45 hypertensive patients, hepatic CMKLR1 mRNA was not changed
(data not shown). CMKLR1 mRNA was elevated in the 15 patients with type 2 diabetes (Figure 2G).
Type 2 diabetes is a risk factor for NAFLD [2] and the NASH score was significantly higher (p = 0.001)
in this group.
In the NASH group 11 patients had diabetes, and here, CMKLR1 mRNA was comparable to that
of non-diabetic NASH patients (p = 0.201, Figure 2H). Similarly, CMKLR1 mRNA was unchanged in the
10 patients with NASH and hypercholesterolemia (p = 0.935) and the 17 hypertensive NASH patients
(p = 0.367) compared to NASH patients not suffering from these co-morbidities (data not shown).
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steatohepatitis (NASH) score (N) <5 and ≥5; (B) CMKLR1 in controls and patients with a NASH score 
<5 compared to those with NASH; (C) Receiver operating characteristic (ROC) curve analysis;  
(D) Correlation of hepatic CMKLR1 mRNA with inflammation; (E) Correlation of hepatic CMKLR1 
mRNA with fibrosis; (F) Correlation of hepatic CMKLR1 mRNA with the NASH score; (G) CMKLR1 
mRNA in patients with and without type 2 diabetes; (H) CMKLR1 mRNA in NASH patients with 
and without type 2 diabetes. The p-values for significant differences/correlations are shown in  
the figure. 
2.3. Hepatic CMKLR1 mRNA in Females 
Recently, gender-specific associations of hepatic CMKLR1 expression with liver histology have 
been identified in chronic hepatitis [16]. Therefore, CMKLR1 mRNA was analyzed in both genders 
separately. In the female patients 22 had a normal weight, 15 were overweight and 19 were obese. 
CMKLR1 mRNA expression was, however, not associated with BMI (r = 0.031, p = 0.823; Figure 3A). 
Of the 56 female patients, 17 had normal liver, 25 borderline NASH and 14 NASH. CMKLR1 mRNA 
was similarly expressed in the three groups (Figure 3B). There was no difference in the hepatic levels 
of CMKLR1 mRNA compared to the combined values of the controls and those with borderline 
NASH (p = 0.609). CMKLR1 mRNA did not correlate with steatosis grade (r = 0.075, p = 0.582), 
inflammation (r = 0.054, p = 0.693), fibrosis (r = 0.248, 0.068) and NASH score (r = 0.137, p = 0.314) 
(Figure 3C and data not shown). Alanine aminotransferase (r = −0.040, p = 0.787), aspartate 
Figure 2. C KLR1 RNA (nor alized for 18S rRNA) in non-alcoholic fatty liver disease (NAFLD).
(A) CMKLR1 mRNA in liver tissues of patients with healthy liver (Cont.), a non-alcoholic steatohepatitis
(NASH) score (N) <5 and ≥5; (B) CMKLR1 in controls and patients with a NASH score <5 compared
to those with NASH; (C) Receiver operating characteristic (ROC) curve analysis; (D) Correlation of
hepatic CMKLR1 mRNA with inflam ation; (E) Correlation of hepatic CMKLR1 mRNA with fibrosis;
(F) Correlation of hepatic MKLR1 mRNA with the NASH score; (G) CMKLR1 mRNA in patients with
and without type 2 diabetes; (H) CMKLR1 mRNA in NASH patients with and without ty e 2 diabetes.
The p-values for signific nt differences/correlation are shown in th figure.
2.3. Hepatic CMKLR1 mRNA in Females
Recently, gender-specific associations of hepatic CMKLR1 expression with liver histology have
been identified in chronic hepatitis [16]. Therefore, CMKLR1 mRNA was analyzed in both genders
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separately. In the female patients 22 had a normal weight, 15 were overweight and 19 were obese.
CMKLR1 mRNA expression was, however, not associated with BMI (r = 0.031, p = 0.823; Figure 3A).
Of the 56 female patients, 17 had normal liver, 25 borderline NASH and 14 NASH. CMKLR1 mRNA
was similarly expressed in the three groups (Figure 3B). There was no difference in the hepatic levels
of CMKLR1 mRNA compared to the combined values of the controls and those with borderline NASH
(p = 0.609). CMKLR1 mRNA did not correlate with steatosis grade (r = 0.075, p = 0.582), inflammation
(r = 0.054, p = 0.693), fibrosis (r = 0.248, 0.068) and NASH score (r = 0.137, p = 0.314) (Figure 3C and data
not shown). Alanine aminotransferase (r = −0.040, p = 0.787), aspartate aminotransferase (r = −0.234,
p = 0.113), alkaline phosphatase (r = 0.170, p = 0.249), and bilirubin (r = −0.066, p = 0.647) in serum
were not associated with hepatic CMKLR1 mRNA (data not shown).
CMKLR1 levels tended to be increased in the six females with hypercholesterinemia (Figure 3D).
There was a modest trend to a higher expression in the liver of the five females with type 2 diabetes
(p = 0.103, Figure 3E). CMKLR1 expression was not related to hypertension diagnosed in 16 females
(data not shown).
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NASH patients compared to those with borderline NASH and controls. When the last two cohorts were
combined, CMKLR1 mRNA was lower compared to that of NASH patients (Figure 4C). ROC analysis
(Figure 4D) revealed an AUC of 0.723. The optimal cut-off point was 1.7 with a sensitivity of 88% and
a specificity of 48% to detect NASH. CMKLR1 mRNA positively correlated with inflammation score
(r = 0.404, p = 0.001), fibrosis score (r = 0.555, p < 0.001; Figure 4E) and NASH score (r = 0.392, p = 0.002).
Alanine aminotransferase (r = 0.028, p = 0.839), aspartate aminotransferase (r = 0.055, p = 0.705),
alkaline phosphatase (r = 0.225, p = 0.108) and bilirubin (r = −0.132, p = 0.346) in serum were not
associated with hepatic CMKLR1 mRNA (data not shown).
In males, CMKLR1 expression tended to be higher in the 10 patients with type 2 diabetes (p = 0.058,
Figure 4F). Expression was not related to hypertension (29 patients) and hypercholesterinemia
(8 patients) (Figure 4G and data not shown).
1 
 
 
Figure 4. CMKLR1 mRNA (normalized for 18S rRNA) in male NAFLD patients. (A) CMKLR1 mRNA
in the liver of normal-weight (BMI ≤ 25 kg/m2), overweight (BMI > 25 and < 30 kg/m2) and obese
(BMI≥ 30 kg/m2) male patients; (B) CMKLR1 mRNA in liver tissues of male patients with healthy liver
(Cont.), a NASH score (N) <5 and ≥5; (C) CMKLR1 in male controls and borderline NASH compared
to male NASH patients; (D) ROC analysis; (E) Correlation of hepatic CMKLR1 mRNA in males with
fibrosis; (F) Hepatic CMKLR1 mRNA in males with and without type 2 diabetes (T2D); (G) Hepatic
CMKLR1 in males with and without hypercholesterolemia. The p-values for significant differences are
shown in the figure. Numbers in brackets indicate a trend.
To exclude that the higher number of type 2 diabetic patients accounts for associations of CMKLR1
mRNA with NASH in male patients; correlation analysis was performed using data of the 52 males
without this co-morbidity. CMKLR1 mRNA still correlated with inflammation (r = 0.378, p = 0.006),
fibrosis (r = 0.547, p < 0.001) and NASH score (r = 0.312, p = 0.024).
3. Discussion
We present evidence that hepatic CMKLR1 mRNA expression is associated with NASH in male
patients. Here, positive correlations of CMKLR1 mRNA with inflammation score, fibrosis score
and consequently NASH score have been identified. The correlation coefficients are rather low but
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associations are highly significant. In females, hepatic CMKLR1 expression is not related to features
of NASH. Although the current study could not identify increased CMKLR1 expression in human
NASH, a recent study reported elevated CMKLR1 in those patients. Gender-related analysis has not
been performed in this cohort [7].
CMKLR1 mRNA is comparable in both genders in the cohort analyzed herein. Levels of mRNA are
also similar in female and male patients with chronic hepatitis C [16]. In hepatitis C patients, CMKLR1
mRNA is not related to inflammation and a negative association with fibrosis has been identified in
females only [16]. CMKLR1 mRNA regulation in chronic liver disease is therefore influenced by gender
and etiology of hepatic injury. The prevalence of NASH is higher in males, and this may be due to
the fact that sex hormones affect NASH severity [17,18]. Modest upregulation of CMKLR1 in male
NASH patients obviously contributes an additional factor responsible for gender-related differences in
NASH pathology.
Obesity is a risk factor for NAFLD [1]. The mature-onset obesity phenotype has been observed in
male but not female CMKLR1-deficient mice [12]. Our results do not show any relation between hepatic
CMKLR1 mRNA and BMI, arguing against an association of liver CMKLR1 levels and body weight.
Interestingly, hepatic CMKLR1 tends to be increased in type 2 diabetes patients in both genders
and upregulation is significant in the whole cohort. This suggests that elevated CMKLR1 mRNA in
the liver of these patients is not necessarily related to NASH which has a higher prevalence in type 2
diabetes [2]. There is, however, no difference in CMKLR1 mRNA in male NASH patients with and
without type 2 diabetes. Hypercholesterinemia in females is also linked to an increase in hepatic
CMKLR1. Blockage of cholesterol synthesis in adipocytes does not affect CMKLR1 protein levels,
while chemerin is strongly reduced [19]. In hepatocytes, elevation of cellular cholesterol does not
change CMKLR1 protein [15]. Therefore, CMKLR1 levels seem not to be related to cellular cholesterol
concentrations. Dyslipidemia may nevertheless affect hepatic CMKLR1 activity in females independent
of NAFLD. A limitation of the current study is the relatively low number of patients with type 2
diabetes and hypercholesterolemia. There are no patients suffering from these co-morbidities in the
control group and only few patients in the borderline NASH group. Therefore, the association of
CMKLR1 with type 2 diabetes and/or hypercholesterolemia has to be evaluated in different cohorts
using patients who ideally do not suffer from NASH. The main intention of the present study was,
however, to identify NAFLD-related changes of this hepatic chemokine receptor. CMKLR1 mRNA was
still associated with inflammation, fibrosis and NASH score when those suffering from type 2 diabetes
were excluded.
The association of CMKLR1 with NASH score in male NASH patients may suggest a higher
activity of CMKLR1-related signaling pathways.
Chemerin is abundantly expressed in the liver, and in patients with chronic hepatitis C mRNA
levels are similar in males and females [8,16]. In human NASH, hepatic chemerin expression is
induced [7] while Deng et al. described lower levels in human fatty liver [6]. Gender-related regulation
of liver chemerin has not been evaluated so far. Serum chemerin is found increased in females in some
but not all studies [20]. The CMKLR1 receptor is only activated by proteolytic cleaved chemerin [9]
and we are unaware of data on gender-related activation of this adipokine. Additional investigations
are needed to evaluate whether chemerin signaling is indeed enhanced upon higher expression of
hepatic CMKLR1. Further, the physiological and pathophysiological roles of CMKLR1/chemerin
signaling in the liver have to still be clarified.
Resolvin E1 is an additional ligand of CMKLR1 [11]. In ob/ob mice, this lipid ameliorates
insulin sensitivity and hepatic steatosis [21]. In a murine model of liver fibrosis induced by
Schistosoma japonicum infection, resolvin E1 treatment reduces the growth of granulomas and thereby
delays hepatic fibrogenesis [22]. However, resolvin E1 fails to improve liver injury in mice fed
an atherogenic diet to induce NASH [23]. Resolvins are derived from ω-3 polyunsaturated fatty
acids [24] and ethyl-eicosapentanoic acid could not ameliorate NASH in a clinical trial [25]. Therefore,
the potential beneficial effects of resolvins in NASH have to be proven in future studies.
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The non-availability of protein from the respective liver tissues may be considered as a limitation
of our study. Recently, our group has shown that CMKLR1 protein is reduced in human steatotic
liver [15]. However, the liver tissue of only 14 patients was analyzed and gender-related regulation
was not determined.
In summary, the present study demonstrates a weak association of hepatic CMKLR1 expression
with features of NASH in male patients.
4. Materials and Methods
4.1. Study Group
Liver tissues of controls and patients with NAFLD were received and details of the patients
are summarized in Table 1. These samples have been introduced in a recent study [26]. Details of
the histological scoring which was done as described [27] are summarized in Table 2. The scores
were summed up and ranged from 0 to 9. Patients with a score of ≥5 were defined as NASH
patients. Alcohol abuse, viral infections and drugs are known to cause liver injury, and therefore,
these patients were excluded. Indications for surgery was hepatic metastases of extrahepatic tumours
for 70 patients, focal nodular hyperplasia of the liver for nine patients, adenoma for six patients,
cholangiocarcinoma for 15 patients, hepatocellular carcinoma for 12 patients and other diseases
in 6 patients. Only healthy tissue was used for isolation of RNA. Hypertension, hypercholesterolemia
and type 2 diabetes diagnosis had been documented. Serum lipids and glucose were not recorded.
Experimental procedures accord to the guidelines of the charitable state controlled foundation Human
Tissue and Cell Research and the study was authorized by the local ethical committee of the University
of Regensburg (Identification code: 12-101-0048; date: 29 March 2012). The written informed consent
was obtained from each patient.
Table 2. Scoring of steatosis, inflammation and fibrosis.
Scores Description
Steatosis 0 <5% steatosis
Steatosis 1 5%–33% steatosis
Steatosis 2 >33%–66% steatosis
Steatosis 3 >66%
Inflammation 0 No foci/20 × field
Inflammation 1 <2 foci/20 × field
Inflammation 2 2–4 foci/20 × field
Inflammation 3 >4 foci/20 × field
Fibrosis 0 No fibrosis
Fibrosis 1 Zone 3 perisinusoidal/pericellular fibrosis; focally or extensively present
Fibrosis 2 Zone 3 perisinusoidal/pericellular fibrosis with focal or extensive periportal fibrosis
Fibrosis 3 Zone 3 perisinusoidal/pericellular fibrosis and portal fibrosis with focal or extensive bridging fibrosis
Fibrosis 4 Liver cirrhosis
4.2. Monitoring of Gene Expression by Real-Time RT-PCR
The LightCycler FastStart DNA Master SYBR Green I kit from Roche (Mannheim, Germany)
was used for analyzing the expression of mRNA semi-quantitatively by real-time RT-PCR. Total
cellular RNA was reverse transcribed using the Promega Reverse Transcription System (Promega,
Madison, WI, USA). The cDNA was used for amplification in glass capillaries (LightCycler, Roche).
Oligonucleotides were synthesized by Metabion (Planegg-Martinsried, Germany). Real-time RT-PCR
was performed as described and sequencing of the amplified DNA fragments (Geneart, Regensburg,
Germany) confirmed the specificities of the PCRs [19]. Serially diluted cDNA was used to create
a standard curve for each gene analyzed. The second derivative maximum method was used for
quantification with the LightCycler software. Primers to amplify human CMKLR1 were 5′-ACC TGC
ATG GGA AAA TAT CCT-3′ and 5′-GAG GTT GAG TGT GTG GTA GGG-3′. The 18S rRNA was used
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for normalization and amplified with 5′-GAT TGA TAG CTC TTT CTC GAT TCC-3′ and 5′-CAT CTA
AGG GCA TCA CAG ACC-3′.
4.3. Statistical Analysis
Data are displayed as box plots and median, lower and upper quartiles and range of the values
are shown. The Mann-Whitney U Test (SPSS Statistics 21.0 program, IBM, Leibniz Rechenzentrum,
München, Germany) was used for comparison of two data sets and Anova followed by a Dunnett
post-hoc test was used for comparison of three data sets. ROC analysis and Spearman correlation were
done using SPSS Statistics 21.0 program. Youden index was calculated to identify the best cut-off point.
A value of p < 0.05 was regarded as significant. Distribution of gender and co-morbidities listed in
Table 1 was analyzed with the Chi-square test.
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